ZVRA
Zevra Therapeutics IncZevra Therapeutics, Inc.
NASDAQ · HealthcareHealthcare / BiotechnologyBiotechnology
Composite · Score v2
84.1/ 100
Threshold 70.0 · +14.1
Zevra Therapeutics Inc(ZVRA)는 v2 복합 점수 84.1로 임계 70.0를 상회했습니다. 소형·가치·현금·진입 타이밍이 균형을 이룹니다.
Zevra Therapeutics, Inc. (ZVRA) cleared the 70.0 threshold with v2 composite 84.1; size, value, cash, and entry align.
Company profile
Zevra Therapeutics Inc는 Healthcare 분야 Biotechnology 기업입니다.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Size
시가총액 663910656 기준 규모 점수 92.0.
Market cap 663910656 — size score 92.0.
Growth
매출 53.3% / 이익 0.0% (혼합 29.32%) — 지속 가능 성장 점수 99.3.
Revenue 53.3% / earnings 0.0% (blended 29.32%) — sustainable growth score 99.3.
Valuation
PER 12.02, PEG 10.67, FCF수익률 7.29%, PBR 3.21 — 밸류 점수 70.2.
P/E 12.02, PEG 10.67, FCF yield 7.29%, P/B 3.21 — valuation score 70.2.
Entry
12개월 가격대 52.53%, 52주 고점 대비 -24.2% — 진입 점수 75.0.
12M price range 52.53%, -24.2% from 52W high — entry score 75.0.
Momentum
6개월 수익률 30.46% — 보조 모멘텀 점수 73.6.
6M return 30.46% — auxiliary momentum score 73.6.
Quality
ROE 34.8%, ROA 8.74%, FCF/순이익 0.85 — 품질 점수 89.9.
ROE 34.8%, ROA 8.74%, FCF/net income 0.85 — quality score 89.9.
Risks
- 실적 가이던스 하향 시 성장 프리미엄 축소 가능
- Growth premium may compress on guidance cuts
- 글로벌 금리·유동성 변화에 따른 밸류에이션 리레이팅
- Valuation re-rating risk from rates and liquidity
- 5년 10배는 목표 시나리오이며 달성을 보장하지 않음
- 10x in five years is a scenario, not a guarantee